[go: up one dir, main page]

PE20081000A1 - Nuevos analogos del peptido intestinal vasoactivo - Google Patents

Nuevos analogos del peptido intestinal vasoactivo

Info

Publication number
PE20081000A1
PE20081000A1 PE2007000873A PE2007000873A PE20081000A1 PE 20081000 A1 PE20081000 A1 PE 20081000A1 PE 2007000873 A PE2007000873 A PE 2007000873A PE 2007000873 A PE2007000873 A PE 2007000873A PE 20081000 A1 PE20081000 A1 PE 20081000A1
Authority
PE
Peru
Prior art keywords
lys
ala
vasoactive intestinal
cameval
gln
Prior art date
Application number
PE2007000873A
Other languages
English (en)
Inventor
David Robert Bolin
Hanspeter Michel
Wajihja Khan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38786842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081000(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081000A1 publication Critical patent/PE20081000A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO ANALOGO CICLICO DEL PEPTDO INTESTINAL VASOACTIVO DE FORMULA (I), EN DONDE X ES H DEL AMINO N-TERMINAL DE His OPCIONALMENTE SUSTITUIDA POR UN PROTECTOR AMINA HIDROLIZABLE, PREFERIBLEMENTE ACETILO; Y ES EL OH DEL CARBOXILO C-TERMINAL DE LA Thr OPCIONALMENTE SUSTITUIDO POR UN PROTECTOR CARBOXILO HIDROLIZABLE PREFERIBLEMENTE NH2; LOS RESIDUOS SUBRAYADOS INDICAN UNA UNION COVALENTE DE CADENA LATERAL DEL PRIMER AMINOACIDOS (Lys21) Y EL ULTIMO (Asp25) DENTRO DEL SEGMENTO; R2 ES Ser O Ala; R5 ES Thr, Ser, Asp, Gln, Pro O CaMeVal, R16 ES Gln, Ala O Arg; R18 ES Ala, Lys O Glu; R27 ES Lys O Leu CON LA EXCEPCION DE QUE R27 DEBE SER Lys CUANDO R5 ES CaMeVal Y R16 ES Arg; R28 ES Lys O Asn. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE PUEDE SER ADMINISTRADO MEDIANTE INHALACION. ESTOS COMPUESTOS SON AGONISTAS ACTIVOS DEL RECEPTOR VPAC-2 Y POSEEN ESTABILIDAD FRENTE A LA ELASTASA DE NEUTROFILOS, POR LO QUE SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DE LAS VIAS RESPIRATORIAAS TAL COMO ENFERMEDADES OBSTRUCTIVAS PULMONARES
PE2007000873A 2006-07-06 2007-07-05 Nuevos analogos del peptido intestinal vasoactivo PE20081000A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81880506P 2006-07-06 2006-07-06

Publications (1)

Publication Number Publication Date
PE20081000A1 true PE20081000A1 (es) 2008-08-06

Family

ID=38786842

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000873A PE20081000A1 (es) 2006-07-06 2007-07-05 Nuevos analogos del peptido intestinal vasoactivo

Country Status (20)

Country Link
US (1) US20080096807A1 (es)
EP (1) EP2041168A2 (es)
JP (1) JP2009542593A (es)
KR (1) KR20090027239A (es)
CN (1) CN101484468A (es)
AR (1) AR061825A1 (es)
AU (1) AU2007271274A1 (es)
BR (1) BRPI0714306A2 (es)
CA (1) CA2656757A1 (es)
CL (1) CL2007001956A1 (es)
CR (1) CR10518A (es)
EC (1) ECSP099029A (es)
IL (1) IL196122A0 (es)
MA (1) MA30590B1 (es)
MX (1) MX2009000013A (es)
NO (1) NO20090027L (es)
PE (1) PE20081000A1 (es)
RU (1) RU2009103811A (es)
TW (1) TW200819139A (es)
WO (1) WO2008003612A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012012383A (es) 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
CN102827268B (zh) * 2011-06-13 2016-08-24 中肽生化有限公司 新型血管肠肽类似物及其制备方法和用途
US8866872B2 (en) 2011-06-21 2014-10-21 Mitel Networks Corporation Conferencing and collaboration system and methods thereof
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
EP3139949B1 (en) * 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
ITUB20159175A1 (it) * 2015-12-23 2017-06-23 Materie Plastiche Pisane S R L Composizione polimerica antibatterica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879371A (en) * 1971-09-17 1975-04-22 Sami I Said Isolation of vasoactive intestinal peptide
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
GB8525852D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4835252A (en) * 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
CN1186355C (zh) * 1996-02-09 2005-01-26 霍夫曼-拉罗奇有限公司 血管活性肠肽类似物的合成
US20050203009A1 (en) * 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
CA2577326A1 (en) * 2004-08-18 2006-03-02 Eli Lilly & Company Selective vpac2 receptor peptide agonists
CA2584095A1 (en) * 2004-10-08 2006-04-20 Forbes Medi-Tech (Research) Inc. Vasoactive intestinal polypeptide pharmaceuticals

Also Published As

Publication number Publication date
IL196122A0 (en) 2011-08-01
EP2041168A2 (en) 2009-04-01
MA30590B1 (fr) 2009-07-01
NO20090027L (no) 2009-01-15
KR20090027239A (ko) 2009-03-16
AR061825A1 (es) 2008-09-24
WO2008003612A3 (en) 2008-02-28
US20080096807A1 (en) 2008-04-24
AU2007271274A1 (en) 2008-01-10
MX2009000013A (es) 2009-01-23
CL2007001956A1 (es) 2008-04-18
CN101484468A (zh) 2009-07-15
TW200819139A (en) 2008-05-01
JP2009542593A (ja) 2009-12-03
CA2656757A1 (en) 2008-01-10
CR10518A (es) 2009-01-27
WO2008003612A2 (en) 2008-01-10
ECSP099029A (es) 2009-02-27
RU2009103811A (ru) 2010-08-20
BRPI0714306A2 (pt) 2014-05-20

Similar Documents

Publication Publication Date Title
PE20081000A1 (es) Nuevos analogos del peptido intestinal vasoactivo
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2013515057A5 (es)
JP2013515055A5 (es)
JP2012518035A5 (es)
AR066847A1 (es) Polipeptidos, dominios variables de anticuerpos, anticuerpos y antagonistas que se unen al receptor de interleuquina-1 del tipo 1
RU2011134596A (ru) Аналоги оксинтомодулина
JP2014129355A5 (es)
ES2324481T3 (es) Tratamiento de infecciones bacterianas.
TWI388333B (zh) 具有改良性質之重組表面張力素
JP2015532307A5 (es)
BR112012014475A2 (pt) derivados de glp-acilados.
ES2373824T3 (es) Péptidos con propiedades mejoradas que tienen la actividad biológica del péptido intestinal vasoactivo (piv) y su uso para el tratamiento de enfermedades pulmonares.
TWI455721B (zh) 癌疫苗組合物
KR20210061372A (ko) 몬테루카스트와 펩티드의 새로운 접합체
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip
BR122020011001B1 (pt) Peptídeo derivados de oxintomodulina e seu uso, polinucleotídeo, composição farmacêutica e seu uso e método para prevenção ou tratamento da obesidade compreendendo os mesmos
CA2555894A1 (en) Pancreatic polypeptide family motifs and polypeptides comprising the same
BR112013026195A2 (pt) derivados de glp-1 duplamente acilados
MX2024005173A (es) Composicion farmaceutica que comprende hialuronidasa humana ph20 y farmaco.
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2019533722A5 (es)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
TW201629085A (zh) 芋螺毒素(conotoxin)肽之修飾及用途

Legal Events

Date Code Title Description
FD Application declared void or lapsed